With the continuous progress of science and technology, mankind's understanding of life sciences is deepening. In this process, by virtue of its excellent R&D strength and innovation ability, InnoModels Biotechnology has successfully built an ADCC (Antibody Dependent Cytotoxicity) in vitro killing experimental platform, which opens up a new path for the research and development of tumor immunotherapy.
InnoModels' ADCC platform leads the development of tumor immunotherapy field with its unique advantages. Firstly, the platform adopts humanized mouse model (HIS) and humanized tumor xenograft platform (PDX), which makes the experimental data closer to the clinical reality, and provides a more accurate and reliable basis for the development of new drugs. Secondly, by utilizing the key players of natural immune response such as NK cells, the ADCC platform is able to efficiently attack tumor cells labeled by antibodies, providing strong support for tumor immunotherapy.

In the field of tumor immunotherapy, InnoModels' ADCC platform not only has a wide range of application prospects, but also has high practical value. On the one hand, through the platform, researchers can conduct in-depth studies on different types of tumor cells, further revealing the mechanisms of tumor development and progression, and providing scientific basis for early diagnosis, treatment and prevention of tumors. On the other hand, the ADCC platform can also provide powerful support for the development of new drugs, helping researchers screen out drugs with efficient anti-tumor activity and provide patients with safer and more effective treatment options.
It is worth mentioning that InnoModels Biotechnology always adheres to a patient-centered approach and is committed to providing individualized medical solutions for patients. Through the ADCC platform, doctors can formulate more precise and personalized treatment plans for patients' specific conditions, improving treatment effects and reducing treatment costs, so that patients can truly benefit.
In conclusion, with its unique advantages and application value, InnoModels' ADCC platform is leading the development of the tumor immunotherapy field. In this era full of challenges and opportunities, InnoModels Biotechnology will continue to uphold the spirit of innovation and pragmatism, and make greater contributions to the cause of human health.